In a recent clinical trial using T cells modified to express an anti-CEA TCR for treating CEA+ metastatic colorectal cancer, severe autoimmune colitis and pneumonia was observed in all of the three patients and led to the halt of the trial (48). Here, CEACAM5 is linked to susceptibility to pneumonia measurement.